Bjermer Leif
Department of Respiratory Medicine & Allergology, University Hospital, Lund, Sweden.
Ther Adv Respir Dis. 2008 Jun;2(3):149-61. doi: 10.1177/1753465808092280.
Combination therapies with inhaled corticosteroids (ICS) and either long-acting beta2 agonists (LABA) or leukotriene receptor antagonists (LTRA) are commonly used to help patients maintain control of their asthma. LABA and LTRA have different mechanisms of action and both provide complementary benefits when combined with ICS. This paper compares the two regimens based on recent clinical trial data, evaluates their efficacy on various clinical and quality of life outcomes, and discusses the importance of therapy choice in people with specific asthma phenotypes. The potential of new dosing strategies, including adjustable maintenance therapy and single-inhaler maintenance and reliever therapy is also reviewed. Given the variety of outcomes, phenotypes, and treatment strategies that must be considered, the importance of individualized management is emphasized.
吸入性糖皮质激素（ICS）与长效β2受体激动剂（LABA）或白三烯受体拮抗剂（LTRA）联合治疗常用于帮助患者维持哮喘控制。LABA和LTRA具有不同的作用机制，与ICS联合使用时均能提供互补的益处。本文基于近期临床试验数据对这两种治疗方案进行比较，评估它们对各种临床和生活质量结局的疗效，并讨论针对特定哮喘表型患者选择治疗方法的重要性。还综述了新给药策略的潜力，包括可调整维持治疗和单吸入器维持及缓解治疗。鉴于必须考虑的结局、表型和治疗策略多种多样，强调了个体化管理的重要性。
